Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVTXNASDAQ:CMLTNASDAQ:NLTXNASDAQ:SNSENASDAQ:VINC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$13.00+6.5%$8.64$3.95▼$1,130.40$13.39M1.13554,687 shs73,223 shsCMLTCM Life Sciences III$8.69$9.37$8.29▼$11.10$180.10MN/A284,659 shs563,420 shsNLTXNeoleukin Therapeutics$31.17+1.8%$37.17$2.03▼$14.36$292.94M1.1150,104 shs58,205 shsSNSESensei Biotherapeutics$1.00+7.5%$0.96$0.51▼$1.72$25.01M0.1665,081 shs85,180 shsVINCVincerx Pharma$0.95+9.2%$4.13$0.61▼$9.37$20.34M1.091.27 million shs420,238 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+4.99%-19.88%+150.20%+168.35%-98.25%CMLTCM Life Sciences III0.00%0.00%0.00%0.00%0.00%NLTXNeoleukin Therapeutics0.00%+118.41%-38.87%+0.49%+79.35%SNSESensei Biotherapeutics-4.03%-7.37%-20.44%+22.15%-38.35%VINCVincerx Pharma+2.24%-0.11%-82.69%-24.43%-8.55%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo Therapeutics0.2763 of 5 stars0.02.00.00.03.71.70.0CMLTCM Life Sciences IIIN/AN/AN/AN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASNSESensei Biotherapeutics3.9724 of 5 stars3.53.00.04.80.01.71.3VINCVincerx Pharma2.2881 of 5 stars3.54.00.00.01.72.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics2.50Moderate BuyN/AN/ACMLTCM Life Sciences IIIN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/A$30.00-3.75% DownsideSNSESensei Biotherapeutics3.00Buy$4.00300.92% UpsideVINCVincerx Pharma3.00Buy$5.00426.32% UpsideCurrent Analyst RatingsLatest NLTX, SNSE, CMLT, VINC, and AVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024AVTXAvalo TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform4/9/2024VINCVincerx PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight4/1/2024VINCVincerx PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$1.92M6.97N/AN/A$9.11 per share1.43CMLTCM Life Sciences IIIN/AN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$2.60 per shareN/AVINCVincerx PharmaN/AN/AN/AN/A$0.52 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$31.54M-$616.67N/AN/AN/A-1,639.50%-1,439.87%-113.95%5/2/2024 (Estimated)CMLTCM Life Sciences IIIN/AN/A0.00∞N/AN/AN/AN/AN/ANLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ASNSESensei Biotherapeutics-$34.10M-$1.22N/AN/AN/AN/A-44.01%-38.58%5/14/2024 (Estimated)VINCVincerx Pharma-$40.16M-$1.89N/AN/AN/AN/A-187.73%-126.26%5/9/2024 (Estimated)Latest NLTX, SNSE, CMLT, VINC, and AVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2024Q4 2023SNSESensei Biotherapeutics-$0.32-$0.30+$0.02-$0.30N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ACMLTCM Life Sciences IIIN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/AVINCVincerx PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A1.821.82CMLTCM Life Sciences IIIN/A1.031.03NLTXNeoleukin TherapeuticsN/A15.3315.33SNSESensei Biotherapeutics0.0111.9211.92VINCVincerx PharmaN/A2.632.63OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%CMLTCM Life Sciences III88.48%NLTXNeoleukin Therapeutics52.37%SNSESensei Biotherapeutics10.50%VINCVincerx Pharma44.02%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics0.20%CMLTCM Life Sciences IIIN/ANLTXNeoleukin Therapeutics1.58%SNSESensei Biotherapeutics25.50%VINCVincerx Pharma20.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics191.03 million1.03 millionNot OptionableCMLTCM Life Sciences IIIN/A20.73 millionN/ANot OptionableNLTXNeoleukin Therapeutics79.40 million9.25 millionOptionableSNSESensei Biotherapeutics2825.07 million18.68 millionNot OptionableVINCVincerx Pharma4121.41 million17.00 millionNot OptionableNLTX, SNSE, CMLT, VINC, and AVTX HeadlinesSourceHeadlineVincerx Pharma, Inc. Common Stock (VINC)nasdaq.com - April 23 at 2:06 AMAACR: Biotechs emerge frostbitten from ‘nuclear winter,’ ready to show why they fought for survivalfiercebiotech.com - April 18 at 12:36 PMAnalyzing Revelation Biosciences (NASDAQ:REVB) and Vincerx Pharma (NASDAQ:VINC)americanbankingnews.com - April 16 at 2:40 AMAgendia’s BluePrint Included in German Oncology Group Guidelinesfinance.yahoo.com - April 12 at 9:45 AMVaccines, Next-Gen Approaches Target the Toughest Cancers: AACRbiospace.com - April 12 at 9:45 AMThe Rise of Zyn: The Oral Nicotine Product Going Viralfinance.yahoo.com - April 10 at 4:08 PMVincerx Pharma Inc (VINC) Gets a Buy from Leerink Partnersmarkets.businessinsider.com - April 10 at 9:44 AMVincerx (VINC) Tumbles on Results From Cancer Therapy Studyzacks.com - April 9 at 2:36 PMACOR, HUBC and DATS among pre-market losersmsn.com - April 9 at 9:19 AMVincerx in selloff after early-stage data for cancer therapymsn.com - April 9 at 9:19 AMCantor Fitzgerald Reaffirms Overweight Rating for Vincerx Pharma (NASDAQ:VINC)marketbeat.com - April 9 at 8:49 AMWhy Is Vincerx Pharma (VINC) Stock Down 64% Today?investorplace.com - April 9 at 8:40 AMVincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024globenewswire.com - April 8 at 4:30 PMFY2024 EPS Estimates for Vincerx Pharma, Inc. Raised by Analyst (NASDAQ:VINC)marketbeat.com - April 4 at 9:13 AMQ1 2024 EPS Estimates for Vincerx Pharma, Inc. (NASDAQ:VINC) Boosted by Leerink Partnrsmarketbeat.com - April 3 at 6:00 AMVINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023investorplace.com - April 2 at 8:06 AMVincerx Pharma, Inc.: Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updatefinanznachrichten.de - April 1 at 4:30 PMVincerx Pharma (NASDAQ:VINC) Receives Overweight Rating from Cantor Fitzgeraldmarketbeat.com - April 1 at 12:23 PMVincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024finance.yahoo.com - April 1 at 10:47 AMVincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close Lookfinance.yahoo.com - March 29 at 8:49 PMVincerx Pharma Cuts Funding-Sufficiency View to 3Q From Late 2024marketwatch.com - March 29 at 3:48 PMVincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updateglobenewswire.com - March 29 at 3:20 PMShort Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Expands By 95.2%marketbeat.com - March 28 at 8:34 AMVincerx Pharma (VINC) Set to Announce Earnings on Tuesdaymarketbeat.com - March 25 at 7:31 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideIntuitive Surgical Leads the Robotic Surgery MovementApril 22, 2024 6:10 AMView Intuitive Surgical Leads the Robotic Surgery MovementAll Headlines Company DescriptionsAvalo TherapeuticsNASDAQ:AVTXAvalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.CM Life Sciences IIINASDAQ:CMLTCM Life Sciences III Inc. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.Neoleukin TherapeuticsNASDAQ:NLTXNeoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Sensei BiotherapeuticsNASDAQ:SNSESensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.Vincerx PharmaNASDAQ:VINCVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.